Related Experiment Video
Updated: Nov 3, 2025

Ultrasonic Assessment of Myocardial Microstructure
Published on: January 14, 2014
Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and
Raluca B Dumitru1,2, Lesley-Anne Bissell1,2, Bara Erhayiem3
1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Insights
Subclinical heart involvement in SSc patients is common, characterized by reduced heart muscle blood flow and fibrosis. Cardiovascular MRI can identify these changes and predict risks associated with disease severity.
Area of Science:
- Cardiology
- Radiology
- Rheumatology
Background:
- Systemic sclerosis (SSc) primary heart involvement (SSc-pHI) is a major cause of mortality.
- Early detection of subclinical SSc-pHI is crucial for risk stratification and management.
Purpose of the Study:
- To characterize subclinical SSc-pHI using cardiovascular MRI.
- To identify predictors of subclinical SSc-pHI in SSc patients without prior cardiovascular disease.
Main Methods:
- 83 SSc patients and 44 healthy controls underwent 3 Tesla contrast-enhanced cardiovascular MRI, including T1 mapping and quantitative stress perfusion.
- Blood biomarkers including high-sensitivity troponin I and N-terminal pro-brain natriuretic peptide were measured.
Main Results:
- SSc patients showed significantly lower myocardial perfusion reserve and higher extracellular volume (ECV) compared to controls, indicating microvascular dysfunction and diffuse fibrosis.
- Late gadolinium enhancement (focal fibrosis) was present in 17% of SSc patients.
- Higher ECV and impaired perfusion reserve were associated with SSc disease severity (skin score) and digital ulcers.
Conclusions:
- Subclinical SSc-pHI is characterized by myocardial microvasculopathy and fibrosis, but preserved contractile function.
- Biomarkers and MRI findings correlate with SSc disease severity and complications.
- Cardiovascular MRI provides insights into SSc-pHI pathophysiology and aids in identifying at-risk individuals.
Objectives:
SSc primary heart involvement (SSc-pHI) is a significant cause of mortality. We aimed to characterize and identify predictors of subclinical SSc-pHI using cardiovascular MRI.
Methods:
A total of 83 SSc patients with no history of cardiovascular disease or pulmonary arterial hypertension and 44 healthy controls (HCs) underwent 3 Tesla contrast-enhanced cardiovascular MRI, including T1 mapping and quantitative stress perfusion. High-sensitivity troponin I and N-terminal pro-brain natriuretic peptide were also measured.
Results:
Cardiovascular MRI revealed a lower myocardial perfusion reserve in the SSc patients compared with HCs {median (interquartile range (IQR)] 1.9 (1.6-2.4) vs 3 (2-3.6), P < 0.001}. Late gadolinium enhancement, indicating focal fibrosis, was observed in 17/83 patients but in none of the HCs, with significantly higher extracellular volume (ECV), suggestive of diffuse fibrosis, in SSc vs HC [mean (s.d.) 31 (4) vs 25 (2), P < 0.001]. Presence of late gadolinium enhancement and higher ECV was associated with skin score [odds ratio (OR) = 1.115, P = 0.048; R2 = 0.353, P = 0.004], and ECV and myocardial perfusion reserve was associated with the presence of digital ulcers at multivariate analysis (R2 = 0.353, P < 0.001; R2 = 0.238, P = 0.011). High-sensitivity troponin I was significantly higher in patients with late gadolinium enhancement, and N-terminal pro-brain natriuretic peptide was associated with ECV (P < 0.05).
Conclusion:
Subclinical SSc-pHI is characterized by myocardial microvasculopathy, diffuse and focal myocardial fibrosis but preserved myocardial contractile function. This subclinical phenotype of SSc-pHI was associated with high-sensitivity troponin I, N-terminal pro-brain natriuretic peptide, SSc disease severity and complicated peripheral vasculopathy. These data provide information regarding the underlying pathophysiological processes and provide a basis for identifying individuals at risk of SSc-pHI.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Myocarditis I: Introduction
Cardiomyopathy I: Introduction and Classification
Myocarditis II: Clinical Features and Diagnostic Tests
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Rheumatic Heart Disease I: Introduction

